This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kaye, K. S.
Right arrow Articles by Carmeli, Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kaye, K. S.
Right arrow Articles by Carmeli, Y.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, September 2001, p. 2628-2630, Vol. 45, No. 9
0066-4804/01/$04.00+0   DOI: 10.1128/AAC.45.9.2628-2630.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.

Risk Factors for Emergence of Resistance to Broad-Spectrum Cephalosporins among Enterobacter spp.

Keith S. Kaye,1,* Sara Cosgrove,1 Anthony Harris,2 George M. Eliopoulos,1 and Yehuda Carmeli1

Division of Infectious Diseases and Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts,1 and the Division of Healthcare Outcomes, Department of Epidemiology and Preventive Medicine, University of Maryland, Baltimore, Maryland2

Received 25 January 2001/Returned for modification 19 March 2001/Accepted 25 May 2001

Among 477 patients with susceptible Enterobacter spp., 49 subsequently harbored third-generation cephalosporin-resistant Enterobacter spp. Broad-spectrum cephalosporins were independent risk factors for resistance (relative risk [OR] = 2.3, P = 0.01); quinolone therapy was protective (OR = 0.4, P = 0.03). There were trends toward decreased risk for resistance among patients receiving broad-spectrum cephalosporins and either aminoglycosides or imipenem. Of the patients receiving broad-spectrum cephalosporins, 19% developed resistance.

* Corresponding author. Mailing address: Duke University Medical Center, Box 3152, Durham, NC 27710. Phone: (919) 668-1720. Fax: (919) 684-3137. E-mail: kaye0001{at}mc.duke.edu.

Antimicrobial Agents and Chemotherapy, September 2001, p. 2628-2630, Vol. 45, No. 9
0066-4804/01/$04.00+0   DOI: 10.1128/AAC.45.9.2628-2630.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Jacoby, G. A. (2009). AmpC {beta}-Lactamases. Clin. Microbiol. Rev. 22: 161-182 [Abstract] [Full Text]  
  • Dong, L., Yan, H., Wang, D. (2008). Antibiotic prescribing patterns in village health clinics across 10 provinces of Western China. J Antimicrob Chemother 62: 410-415 [Abstract] [Full Text]  
  • Marcos, M., Inurrieta, A., Soriano, A., Martinez, J. A., Almela, M., Marco, F., Mensa, J. (2008). Effect of antimicrobial therapy on mortality in 377 episodes of Enterobacter spp. bacteraemia. J Antimicrob Chemother 62: 397-403 [Abstract] [Full Text]  
  • Marchaim, D., Navon-Venezia, S., Schwaber, M. J., Carmeli, Y. (2008). Isolation of Imipenem-Resistant Enterobacter Species: Emergence of KPC-2 Carbapenemase, Molecular Characterization, Epidemiology, and Outcomes. Antimicrob. Agents Chemother. 52: 1413-1418 [Abstract] [Full Text]  
  • Paterson, D. L., Bonomo, R. A. (2005). Extended-Spectrum {beta}-Lactamases: a Clinical Update. Clin. Microbiol. Rev. 18: 657-686 [Abstract] [Full Text]  
  • Szabo, D., Bonomo, R. A., Silveira, F., Pasculle, A. W., Baxter, C., Linden, P. K., Hujer, A. M., Hujer, K. M., Deeley, K., Paterson, D. L. (2005). SHV-Type Extended-Spectrum Beta-Lactamase Production Is Associated with Reduced Cefepime Susceptibility in Enterobacter cloacae. J. Clin. Microbiol. 43: 5058-5064 [Abstract] [Full Text]  
  • Martin, C., Ofotokun, I., Rapp, R., Empey, K., Armitstead, J., Pomeroy, C., Hoven, A., Evans, M. (2005). Results of an antimicrobial control program at a university hospital. Am J Health Syst Pharm 62: 732-738 [Abstract] [Full Text]  
  • Schlesinger, J., Navon-Venezia, S., Chmelnitsky, I., Hammer-Munz, O., Leavitt, A., Gold, H. S., Schwaber, M. J., Carmeli, Y. (2005). Extended-Spectrum Beta-Lactamases among Enterobacter Isolates Obtained in Tel Aviv, Israel. Antimicrob. Agents Chemother. 49: 1150-1156 [Abstract] [Full Text]  
  • Schwaber, M. J., Graham, C. S., Sands, B. E., Gold, H. S., Carmeli, Y. (2003). Treatment with a Broad-Spectrum Cephalosporin versus Piperacillin-Tazobactam and the Risk for Isolation of Broad-Spectrum Cephalosporin-Resistant Enterobacter Species. Antimicrob. Agents Chemother. 47: 1882-1886 [Abstract] [Full Text]  
  • Gesser, R. M., McCarroll, K., Teppler, H., Woods, G. L. (2003). Efficacy of ertapenem in the treatment of serious infections caused by Enterobacteriaceae: analysis of pooled clinical trial data. J Antimicrob Chemother 51: 1253-1260 [Abstract] [Full Text]  
  • Cosgrove, S. E., Kaye, K. S., Eliopoulous, G. M., Carmeli, Y. (2002). Health and Economic Outcomes of the Emergence of Third-Generation Cephalosporin Resistance in Enterobacter Species. Arch Intern Med 162: 185-190 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»